The ALS Therapy Development Institute (ALS TDI) is proud to announce that the first participant was successfully given a dose of AT-1501 in the first clinical trial of the experimental treatment for amyotrophic lateral sclerosis (ALS). The phase 1 safety trial is enrolling healthy volunteers and people living with ALS, following the acceptance of an Investigational New Drug (IND) application by the Food & Drug Administration (FDA). A total of 8 people living with ALS will receive AT-1501 in this study, with the aim of determining safety and tolerability of the experimental antibody. The trial, sponsored by Anelixis Therapeutics, LLC, will also determine the pharmacokinetics of AT-1501, i.e. how the drug acts within the body.
Did you ever stop to think about how water can move? Or think about how people can move as well? I’m not talking about specific actions, but just the basic ability. But there’s a caveat that many people forget: those with ALS lose the natural ability to move as their motor neurons die and their muscles cease functioning.
On Oct. 18, Patty Haberstroh got news no person hopes to receive in her lifetime. She was diagnosed with amyotrophic lateral sclerosis, colloquially known as Lou Gehrig’s disease, a neuromuscular degenerative illness that causes muscle atrophy and the eventual loss of all voluntary muscle control.
When Haberstroh, a Westport resident since 1990, told her husband, Charlie, and their four children of the diagnosis, she said they were understandably upset, but vowed do something and felt they could make a difference in fighting the disease.
When the ALS Therapy Development Institute invited me to speak at their annual White Coat Affair gala last October, I took advantage of the opportunity to tour the Institute’s lab where they are performing fast-track ALS research. While there, our tour passed by the freezer where AT-1501, a potential effective treatment for both ALS and Alzheimer’s, is stored.
I'm thankful for those who support my fundraising efforts for ALS research and for the staff at the ALS Therapy Development Institute.
Kevin Gosnell was a major fundraiser for cystic fybrosis before he was diagnosed with ALS.
Yesterday, the ALS Therapy Development Institute, Massachusetts General Hospital/Harvard Medical School and the University of Massachusetts Medical School partnered to create ALS ONE.
The second ALS Ice Bucket Challenge has just wrapped up. Last year, the fundraiser for Lou Gehrig’s disease – also called amyotrophic lateral sclerosis, or ALS – went viral on the Internet. It raised millions of dollars for research and has spawned a movement, “Every August Until A Cure.”
This year, Here & Now’s Robin Young decided to check in with Corey Reich, the young man from Piedmont, California, we first met in 2011.